Cellectis

YTD

ALL

Why Robinhood?

You can watch Cellectis and buy or sell other stocks, options, and ETFs commission-free!

About CLLS

Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J.

CEO

André Choulika

CEOAndré Choulika

Employees

237

Employees237

Headquarters

Paris, Ile-de-France

HeadquartersParis, Ile-de-France

Founded

1999

Founded1999

Employees

237

Employees237

CLLS Key Statistics

Market cap

187.59M

Market cap187.59M

Price-Earnings ratio

-1.49

Price-Earnings ratio-1.49

Dividend yield

—

Dividend yield—

Average volume

34.49K

Average volume34.49K

High today

$2.61

High today$2.61

Low today

$2.47

Low today$2.47

Open price

$2.47

Open price$2.47

Volume

616.00

Volume616.00

52 Week high

$3.77

52 Week high$3.77

52 Week low

$0.9628

52 Week low$0.9628

CLLS News

TipRanks 3d

Cellectis Unveils Groundbreaking Gene-Editing Advances - TipRanks.com - TipRanks

Cellectis S.A. (CLLS) has released an update. Cellectis S.A., a biotech firm, has announced breakthroughs in gene-editing technology that could significantly a...